Lupin on Friday said it has received approval from US FDA to market a generic product, used in the treatment of a lung disease, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market Pirfenidone tablets in strengths of 267 mg and 801 mg, the Mumbai-based drug maker said in a statement.
